Tillotts in the UK
Tillotts Pharma AG has a strong presence in Europe with affiliates and distributors in all major European markets. The UK business is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, and part of the Japanese Zeria Group.
Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products. Tillotts Pharma UK is now a market leader.
GI health is our passion at Tillotts. With over 30 years’ expertise in developing and manufacturing treatments for inflammatory bowel disease (IBD), we understand the disease, the market and the challenges GI healthcare professionals and patients face. Tillotts Pharma UK strive to be the preferred partner in GI health and are committed to supporting the NHS to improve outcomes for patients. Tillotts are motivated by the aim to consistently deliver quality and value to the NHS and are dedicated to improving the lives of people with GI disease and supporting those who care for them.
Tillotts actively seeks partnership and in-licensing opportunities, to add to our portfolio of medicines for disease of the digestive system. We are particularly interested in products which may be off patent or are currently not being actively promoted where we can breathe life back into the brand, help fulfil any unmet patient needs and provide value to the NHS.
Tillotts Pharma UK have recently received several industry recognised awards, including Gold and Silver PM Society Award 2018 and Gold Communiqué Award 2019 for Excellence in Communication via Meetings. Tillotts Pharma UK has also been recognised internally, winning an internal Star Award for being the best performing affiliate, for maintaining seven consecutive years of double digit growth.